Bernstein reiterates Eli Lilly stock rating with $1,100 price target

Bernstein SocGen Group reiterated an Outperform rating on Eli Lilly (LLY) with a $1,100 price target, expressing increased confidence in its oral GLP-1 candidate, orforglipron, following the EASD conference. This positive outlook is supported by Eli Lilly's 37% LTM revenue growth, promising clinical trial results for Mounjaro and orforglipron, a planned $6.5 billion manufacturing expansion, and 14 upward revisions to analyst earnings estimates.

Analysis

Eli Lilly's strategic position in the GLP-1 market has been significantly reinforced, as evidenced by Bernstein SocGen Group's reiterated 'Outperform' rating and a $1,100 price target. This confidence is underpinned by multiple positive developments, including the company's robust 37% revenue growth over the last twelve months and 14 upward revisions to analyst earnings estimates. Clinically, Eli Lilly has demonstrated a competitive edge; its experimental oral drug, orforglipron, outperformed Novo Nordisk’s oral semaglutide in a head-to-head trial, showing superior results in blood sugar control and weight loss. This, combined with promising pediatric trial data for Mounjaro, strengthens its pipeline. The company is actively addressing future demand and potential supply constraints with a planned $6.5 billion investment in a new manufacturing facility for small molecule synthetic medicines. While the EASD conference largely reaffirmed existing data for both Eli Lilly and Novo Nordisk, the negative sentiment shift for Novo Nordisk (-0.4) versus the strongly positive sentiment for Eli Lilly (0.9) highlights the perceived competitive win for Lilly's pipeline. A minor headwind to monitor is potential regulatory pressure on drug pricing in international markets, as flagged by CEO Dave Ricks' comments regarding UK policy.

Key Decisions for Investors

• Investors should view the positive analyst ratings and strong clinical trial results for orforglipron as a confirmation of Eli Lilly's strengthening leadership position in the lucrative oral GLP-1 market.
• Consider the competitive dynamics, as orforglipron's demonstrated superiority over Novo Nordisk's drug may enable Eli Lilly to capture significant future market share, potentially warranting a re-evaluation of positions in both companies.
• Monitor the execution of the $6.5 billion manufacturing expansion, as the ability to successfully scale production will be critical for meeting projected demand and realizing the full financial potential of its pipeline assets.